ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1078

Elevated Proportion of CD38highIgD+ b Cells in Peripheral Blood Is Related to Disease Activity in Patients with Primary SjöGren’s Syndrome

Eriko Ishioka1, Keiko Yoshimoto2, Katsuya Suzuki3, Ayumi Nishikawa2, Hidekata Yasuoka4, Kunihiro Yamaoka5 and Tsutomu Takeuchi4, 1Connective tissue disease, National Tokyo Medical Center, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 4Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, 5Keio University, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cells and Sjogren's syndrome

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren’s syndrome (pSS) is well recognized as an autoimmune disease accompanied by hypergammaglobulinemia and production of autoantibodies such as anti-Ro/SSA and anti-La/SSB antibodies. Although these serological aberrations suggest that abnormally activated B cells play a key role in the pathogenesis of pSS, the possible involvement of hyperactivated B cells in the development of pSS has not been fully understood. In this study, we tried to identify B cell subsets in peripheral blood which may be responsible for disease activities of pSS.

Methods:  Peripheral blood was collected from pSS patients (n = 34) and gender- matched healthy controls (HC, n = 20), and the proportion of B cell subsets characterized by anti-CD19, anti-IgD and anti-CD38 antibodies was analyzed by flow cytometry. CD19+B cells prepared from pSS patients and HC by using CD19-microbeads were stimulated in vitro with a mixture of an anti-IgM antibody, recombinant human CD40 ligand, recombinant human IL-4 and recombinant human soluble BAFF (B cell stimulation). IgG production by the cells was measured by ELISA. Disease activities of the pSS patients were quantified based on the European League against Rheumatism (EULAR) Primary Sjögren’s syndrome disease activity index (ESSDAI). The serological data of the patients were collected by clinical records.

Results: The proportion of CD19+ B cells was significantly increased in pSS patients as compared with HC. In addition, IgG production by CD19+ B cells in vitro upon B cell stimulation was also significantly increased in pSS patients. Moreover, the IgG production was positively and significantly correlated with serum IgG levels of the patients. Interestingly, FACS analysis of whole blood samples revealed that both CD38highIgD+ and CD38highIgD– B cells were significantly increased in pSS patients compared with HC. Moreover, the number of CD38highIgD+ B cells was significantly higher than that of CD38highIgD– B cells in the patients. In addition, the proportion of CD38highIgD+ B cells to CD19+B cells was positively and significantly correlated with ESSDAI, serum levels of IgG, anti-Ro/SSA and anti-La/SSB antibodies.

Conclusion: Our results suggest that CD38highIgD+ B cells, which are known as activated B cells, are involved in overproduction of IgG and associated with disease activity of pSS. Our findings may shed light on the mechanism of pathogenesis of pSS.


Disclosure: E. Ishioka, None; K. Yoshimoto, None; K. Suzuki, None; A. Nishikawa, None; H. Yasuoka, None; K. Yamaoka, None; T. Takeuchi, AbbVie, Astellas, Bristol-Myers, Chugai, Daiichi Sankyo, Eisai, Janssen, Mitsubishi Tanabe, Nippon Shinyaku, Pfizer, Sanofi, Santen, Takeda, Teijin, 2,AstraZeneca, Eli Lilly, Novartis, Mitsubishi Tanabe, Asahi Kasei Medical, 5,AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi Tanabe, Pfizer, Takeda, 8.

To cite this abstract in AMA style:

Ishioka E, Yoshimoto K, Suzuki K, Nishikawa A, Yasuoka H, Yamaoka K, Takeuchi T. Elevated Proportion of CD38highIgD+ b Cells in Peripheral Blood Is Related to Disease Activity in Patients with Primary SjöGren’s Syndrome [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/elevated-proportion-of-cd38highigd-b-cells-in-peripheral-blood-is-related-to-disease-activity-in-patients-with-primary-sjogrens-syndrome/. Accessed March 1, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-proportion-of-cd38highigd-b-cells-in-peripheral-blood-is-related-to-disease-activity-in-patients-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.